CD274 and neoplasm: Researchers have discovered peptides that inhibit the PD-1/PD-L1 interaction and reactivate T cell function against tumor cells, including peptide-57, CLP001/CLP002, and PD-L1 Pep-1/PD-L1 Pep-2.